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dramatically with increasing age. However, the spleen and MLN differed in their susceptibility to an age-associated decline in immune function. While the PFC responses in the spleen declined with age, the PFC response in the mucosa-associated MLN did not decline with age but instead remained constant over the entire age span of 4 to 28 months studied. These studies showed that the spleen, peripheral lymph nodes, and MLN did not demonstrate parallel age-associated defects in antibody responses to pneumococcal polysaccharides when the antigen was administered systemically. Also, the deficient splenic antibody response to Pnu-Imune vaccine in aged mice could be enhanced by injecting a combination of Pnu-Imune vaccine and the nontoxic adjuvant monophosphoryl lipid A. Moreover, an immunoglobulin G response was induced when the immunogen was a mixture of vaccine and adjuvant.
The immune responses of mice to pneumococcal polysaccharide antigens are remarkably similar to those of humans in that both neonates and aged individuals are hyporesponsive to these antigens (9, 18, 22, 30, 31) . Not surprisingly, there is an increased susceptibility of infants and aged humans to pneumococcal infections (18, 28, 36) . A 23-valent pneumococcal polysaccharide vaccine was developed in 1983 to improve antibody responses in humans to encapsulated bacteria and was found to be protective in young adults but not in infants (8, 20) . The efficacy of this vaccine in the elderly has been extremely controversial (29) . Despite large immunization programs, bacterial pneumonia remains a serious cause of morbidity and mortality throughout the world and a significant cause of illness and death among the elderly. The mechanistic basis of this age-associated variation in immunity to polysaccharide antigens is not known. Further, the mucosal lymphoid apparatus, encompassing over a third of the body's lymphoid tissue and forming the first line of defense in infections, has recently been shown to retain immunocompetence in aged mice (33) . This is interesting in the context of our recent findings which showed that a variety of type 2 thymus-independent antigens (TI-2) elicited excellent antibody responses from the spleen and mesenteric lymph nodes (MLN) but not from peripheral lymph nodes or lungs (15) (16) (17) and because pneumococcal polysaccharides have been considered TI-2 antigens (21) .
To gain further insight into the effects of aging on the immune responses to pneumococcal polysaccharide antigens, we established a murine model system using the Pnu-Imune vaccine as the antigen. The polyvalent pneumococcal vaccine is a mixture of 23 capsular polysaccharides * Corresponding author.
derived from the most commonly occurring serotypes of pneumococcal bacteria (12) . In spite of extensive work with individual polysaccharides in the animal models, very little information is available about the characteristics of the immune responses of mice to this vaccine formulation. Such studies will be extremely important in improving the efficacy of this vaccine in children and the elderly. This work has focused on characterizing murine immune responses to the vaccine and analyzing the age-associated changes in such immune responses in systemic (spleen and peripheral lymph nodes) and mucosa-associated lymphoid organs (MLN (1, 000 ,ug/0.5 ml of packed SRBC) or individual polysaccharide (350 ,ug/0.5 ml of packed SRBC), and coupling with 1.0 ml of 0.1% freshly made chromium chloride solution. The suspension was rocked for 10 min at room temperature. The erythrocytes were then washed four times by centrifugation with 20 volumes of saline and adjusted to a final concentration of 10% (vol/vol) for use in the PFC assays. TNP-SRBC were prepared as described before (17) .
Polyethylene glycol (average molecular weight, 7,500 to 8,000) (J. T (16, 24) .
Statistical analysis. The Student t test was used to assess the significance of the observed differences between groups. The differences were considered to be significant when the probability (P) value was <0.05.
RESULTS
Characterization of immune responses of mice to PnuImune vaccine. A systematic analysis of doses, time periods, and various routes of immunization was performed to establish conditions for obtaining maximum response to the Pnu-Imune vaccine. Figure 1A summarizes the Pnu-Imunespecific response in the spleens and the MLN of BALB/c mice immunized i.p. with various doses of the vaccine. For both lymphoid organs, 11.5 p,g of the vaccine was found to be the optimal dose that elicited the highest response. The PFC response peaked 5 days after i.p. immunization, and the peak responses in the spleen and MLN were obtained on the same day (Fig. 1B) The PFCs detected with the vaccine-coated SRBC were specific to Pnu-Imune vaccine, because the soluble vaccine inhibited the response completely, whereas only 10 to 20% of the response was inhibitable by cell wall polysaccharides or type 3 pneumococcal polysaccharide. The immunization procedure appeared to sensitize mice to almost all the polysaccharides, as determined by using SRBC coated with individual polysaccharides (21 of 23 were tested).
A sample of data (covering the whole spectrum of responses) with several polysaccharides is shown in Table 1 . The response measured on vaccine-coated SRBC was 1,034 ± 141 PFCs/106 spleen cells, whereas the sum of responses measured using individual-polysaccharide-coated SRBC was 2,950 ± 130 PFCs/106 cells, suggesting that the former is on the average 33% as efficient in detecting the response to any individual component.
Differences in splenic and lymph node responses to PnuImune. Previously we reported that TI-2 antigens like TNPFicoll elicited PFC responses from spleen and MLN B cells but not from draining lymph node B cells in the periphery (15, 17) . To determine whether Pnu-Imune vaccine behaved like the other TI-2 antigens and whether MLN response can be obtained by another route of immunization, the vaccine was administered subcutaneously and the PFC response was measured in the peripheral lymph nodes (brachial, axillary, cervical, popliteal, inguinal, and periaortic) and MLN as well as in the spleen. Pnu-Imune vaccine did not elicit any PFC response in the peripheral lymph nodes and MLN but was effective in inducing a good splenic response ( Fig. 2A) . Although the experiment was performed with the optimal dose of the antigen (11.5 ,ug), other doses (higher and lower) of the vaccine were also ineffective in eliciting a PFC response from the peripheral lymph nodes. In the same experiment, TNP-BA, a TI-1 antigen, induced a good PFC (Fig. 3A) . Just as in young mice, 11.5 ,ug continued to be the optimal dose for aged mice, and the peak response was obtained on day 5 (Fig. 3B) Imune vaccine declined steadily with increasing age of the mice. The maximum splenic response occurred in the 4-to 5-month-old mice, and 22-month-old mice exhibited responses which were significantly less (P < 0.001) than the maximum value. The vaccine failed to elicit antibody response from peripheral lymph nodes from mice of all age groups. Interestingly, PFC responses in the mucosa-associated lymph nodes did not decline but instead remained relatively constant over the entire age span studied. In this study, mice younger than 4 months were not tested, but other studies with individual polysaccharides demonstrated that younger mice had reduced responses (21, 22) .
To determine whether senescence had any positive effects on the immune responses of peripheral lymph nodes to the Pnu-Imune vaccine, we immunized 22-to 24-month-old BALB/c mice subcutaneously with this vaccine in the left armpit near the shoulder and into the foot pads. As shown in Table 2 , 22-to 24-month-old mice behaved like young mice and did not show any response in the peripheral or MLN. These lymph node cells responded well to challenge with TNP-BA, consistent with our previous studies on lymph ( node responses to such antigens (15, 17) . Although there was a detectable splenic response to Pnu-Imune in these aged mice, it was small compared with that of young mice.
The nontoxic adjuvant, MPL(A), enhances the immune response to the vaccine. Young mice (4 to 5 months old) and old mice (22 to was found to be optimal in enhancing the Pnu-Imune response in young and old mice, while smaller doses were ineffective as an adjuvant and higher doses of MPL(A) (100 jig) were inhibitory in both young and old mice. At the optimal dose, the MPL(A) adjuvant enhanced the antibody response from the spleens of old mice (22 to 24 months) by a factor of 10 ( Fig. 4A) , but there was little or no response in mice immunized only with the adjuvant. The splenic response of young mice was also enhanced by MPL(A) but only by a factor of about 3. The response in MLN was enhanced by MPL(A) only in young mice. Since, in humans, the i.p. route is not practical, we tested the ability of MPL(A) to be used as an adjuvant if administered via the subcutaneous route. The splenic response increased when Pnu-Imune vaccine was administered subcutaneously along with the MPL(A) adjuvant (Fig. 4B) . The MPL(A)-induced enhancement was greater in old mice than in young mice. However, MPL(A) was unable to induce any Pnu-Imune response in the draining lymph nodes of young or old mice. Injection of MPL(A) 2 days after subcutaneous immunization with the optimal dose (11. The Pnu-Imune vaccine alone induced an IgM PFC response, but no IgG response, in young and old mice. Administration of MPL(A) along with the vaccine induced IgG3 responses in both age groups (Table 3 ). Yet there was no IgGl or IgG2 response, suggesting that the response observed with anti-IgG antibodies is mainly due to the IgG3 component. The isotype distribution of the response remained the same at later times after immunization. Notably, the enhancing effect of MPL(A) on the Pnu-Imune response in the spleen could be observed even at day 11 in 22-monthold mice (Fig. 5) as well as in 6-to 9-month-old mice (data not shown). 
DISCUSSION
An animal model system was developed to study the effect of age on immune responses to the vaccine containing pneumococcal polysaccharides. The commercially available Pnu-Imune vaccine was found to be effective in inducing a good antibody-forming cell response in the murine system. The optimal dose requirements and the peak of the response for the vaccine were similar to those observed with the individual polysaccharides in mice (4 proposed that the mucosa-associated lymphoid system contains a distinct lymphoid population (1, 6, 11, 23) . Indeed, the homing receptors for Peyer's patches and peripheral lymph nodes have been found to be distinct (14) . The reason why the mucosa-associated lymphoid system remains immunologically vigorous at a time when systemic immunity declines is not known but may be related to the constant environmental stimulation present in the mucosal tissues. For practical purposes, it would be valuable if an immunization protocol could recruit this system to obtain a good antibody response to the Pnu-Imune vaccine in aged humans. Currently, we are attempting oral immunization with the vaccine and supplementation with adjuvants to stimulate the mucosal immune system of mice.
Studies by Tomai et al. (35) showed that MPL(A) was a good adjuvant in restoring age-dependent losses in immune responses to SRBC. Later Baker et al. (3) reported that MPL(A) also enhanced the responses of young mice to type III pneumococcal polysaccharides and suggested that MPL(A) may be effective in overcoming the effect of suppressor cells. Even though we do not know whether the age-associated decline in responsiveness to Pnu-Imune vaccine is a result of suppressor function, we found that MPL(A) substantially enhanced the antibody response of aged mice to the Pnu-Imune vaccine. Administration of Pnu-Imune vaccine along with MPL(A) induced a response which remained elevated up to day 11. Also, the adjuvant induced antibodies of IgG and IgG3 subtypes, which usually have longer half-lives than IgM (37) , and thus may prolong protective immunity. Since IgG responses are usually associated with memory, supplemental immunization with the adjuvant might provide an opportunity to obtain secondary responses to the Pnu-Imune vaccine. We are currently investigating this possibility. These results are extremely encouraging, since large doses of MPL(A) have been found to be relatively nontoxic to humans in phase I clinical trials (39) .
Several factors may contribute to the ability of MPL(A) to act as an adjuvant in enhancing the immune response and inducing an isotype switch. First, MPL(A) is mitogenic to B cells and thus may act synergistically with antigen in stimulating B cells (25) . Second, MPL(A) plus trehalose dimycolate mixture activates macrophages and stimulates the production of IL-1 (10, 13, 26, 27, 41 In summary, we have shown that murine immune responses to the Pnu-Imune vaccine declined with age as in humans and could be enhanced with the adjuvant MPL(A). The adjuvant was also effective in inducing an IgG response to the vaccine. The preservation of Pnu-Imune responses in the MLN cells of the elderly suggests that alternative strategies of immunization with the vaccine should be explored.
